Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116753 · ClinicalTrials.gov registry record · Phase 2
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 460
- Enrollment target
NCT00116753: Completed Phase 2 study, sponsored by Ferring Pharmaceuticals.
NCT00116753 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 460 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (246% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116753, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 460 participants
- Enrollment target
Study Summary
The rationale of the study was to evaluate different degarelix dosing regimens for a three-month interval that was to produce and maintain castration in prostate cancer patients through immediate and prolonged testosterone suppression, and to provide confirmatory evidence of the safety of degarelix.
Primary Outcome
Figure in the table give the number of participants with all testosterone values \<=0.5 ng/mL from Day 28 to the end of the study.
Interventions
- DRUG Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00116753 record still lists
NCT00116753 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (246% higher).
The record links to 0 conditions, and to 1 intervention - of which Degarelix is the first listed.
NCT00116753 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00116753 about?
NCT00116753 is a clinical study titled "A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer". The rationale of the study was to evaluate different degarelix dosing regimens for a three-month interval that was to produce and maintain castration in prostate cancer patients through immediate and prolonged testosterone suppression, and to provide confirmatory evidence of the safety of degarelix.
What is the current status of trial NCT00116753?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 460 participants. The study started on 2005-01. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00116753?
The interventions under investigation include: Degarelix (DRUG).
Who is sponsoring clinical trial NCT00116753?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00116753's enrollment target sits among peer trials
460 83rd of 2000 higher than 1,917 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia